Open-access review highlights how cellular senescence, neuroinflammation, and altered neural signaling may link brain aging to tumor biology and cognitive decline.
Brain tumors develop within an organ that changes substantially with age. A new review in Ageing and Cancer Research & Treatment examines evidence that the aging brain microenvironment may influence brain tumor progression, treatment resistance, and cognitive outcomes.
The article, “Navigating the aging brain: The interplay between brain malignancy and the aging microenvironment,” brings together emerging evidence from aging biology, cancer neuroscience, and neuro-oncology. Rather than viewing aging as a background clinical variable, the review proposes that the aging brain may actively shape the biology of tumors that arise within it.
The review highlights several interconnected processes associated with brain aging, including the accumulation of senescent cells, chronic low-grade inflammation, metabolic dysfunction, altered neurotransmitter signaling, ion-channel dysregulation, and blood-brain barrier changes. These processes can collective reshape the neural microenvironment in which tumors arise and progress.
A central focus is the two-way relationship between tumors and the nervous system. Research reviewed in the article indicates that glioma cells can interact functionally with neurons, including through neuron-to-tumor synapses and neurotransmitter signaling. At the same time, brain tumors and their treatment may promote senescence in nearby neurons and glial cells, potentially contributing to a feedback loop involving tumor progression, treatment resistance, and cognitive decline.
The review also examines the dual role of cellular senescence. Senescence can suppress the proliferation of damaged or abnormal cells, but senescent cells can also release inflammatory and tissue-remodeling factors collectively known as the senescence-associated secretory phenotype, or SASP . In an aging brain, the accumulation of senescent neurons, astrocytes, microglia, and endothelial cells may create a microenvironment that supports tumor progression.
Rather than proposing an immediate clinical treatment strategy, the authors outline research directions for age-aware neuro-oncology. These include studying senescence-modulating approaches, neuroinflammation and blood-brain barrier biology, ion channels, neurotransmitter systems, and advanced patient-derived organoid models. The review notes that interventions specifically targeting aging-related mechanisms in brain tumors remain largely preclinical and require direct clinical evaluation.
The authors also emphasize that chronological age alone should not determine care for older people with brain tumors. Tumor molecular features, physiological fitness, frailty, cognitive reserve, neurological function, comorbidites, treatment tolerance, and quality of life should all inform clinical decision-making.
Taken together, the review calls for brain tumor research to consider tumor control and brain health as interconnected outcomes. Understanding how an aging neural microenvironment influences tumor behavior and how tumors reshape that microenvironment, may reveal previously overlooked mechanisms of treatment resistance and neurological decline, while opening new directions for therapies that target both cancer and the aging brain.